Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size

Li, Shengxian; Feng, Xiangru; Wang, Jixue; Xu, Weiguo; Islam, Mohammad Ariful; Sun, Tianmeng; Xie, Zhigang; Wang, Handong; Ding, Jianxun; Chen, Xuesi

doi:10.1002/adfm.201903391

Cited by 42 publications

(36 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the continuous development of nanomedicines, nanoparticles are now considered as a potential cancer treatment with bright future (Ding et al, 2019;Feng et al, 2019;Jiang et al, 2019;Li et al, 2019;Qi et al, 2019;Sun et al, 2019;Wang et al, 2019;Xu et al, 2019;Xiong et al, 2020;Yang et al, 2020). The nanoparticle is small and can facilitate the various biological reactions (Behzadi et al, 2017;Chen et al, 2017a).…”

Section: Introductionmentioning

confidence: 99%

Stannic Oxide Nanoparticle Regulates Proliferation, Invasion, Apoptosis, and Oxidative Stress of Oral Cancer Cells

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Objective: To explore the effects of SnO 2 nanoparticles (NPs) on proliferation, invasion, apoptosis, and oxidative stress of oral cancer. Methods: SnO 2 NPs were prepared and characterized. Oral cancer cell lines CAL-27 and SCC-9 were cultured in vitro. We detected the effects of various concentrations of SnO 2 NPs (0, 5, 25, 50, 100, 200 µg/mL) on the proliferation of oral cancer cells, and observed the morphological changes, and measured the cells ability of migration, invasion and apoptosis condition, and the levels of oxidative stress were measured by detecting malondialdehyde (MDA) and reactive oxygen species (ROS). Besides, we also measured the changes of mRNA and protein levels of factors related to cell proliferation, migration, invasion, apoptosis, and oxidative stress. Results: SnO 2 NPs inhibited the proliferation of oral cancer cells in a concentrationdependent manner (all P < 0.05). And SnO 2 NPs treatment could reduce the migration and invasion ability of cells (all P < 0.05), induce apoptosis, and those effects were better when treated for 48 h than 24 h (all P < 0.05). And SnO 2 NPs could induce oxidative stress in cells (all P < 0.05). Besides, the concentrations of cyclin-D1, C-myc, matrix MMP-9, and MMP-2 in SnO 2 NPs treated group was decreased (all P < 0.05), and the expression levels of cleaved Caspase-3, cleaved Caspase-9, and Cytochrome C were increased (all P < 0.05). Conclusion: In the present study, we found that SnO 2 NPs could play a cytotoxic role in oral cancer cells, and inhibit cell proliferation, migration, and invasion, and induce oxidative stress and apoptosis, which suggests that SnO 2 NPs may have the effects of anti-oral cancer. However, a more in-depth study is needed to determine its roles.

show abstract

Section: Introductionmentioning

confidence: 99%

Stannic Oxide Nanoparticle Regulates Proliferation, Invasion, Apoptosis, and Oxidative Stress of Oral Cancer Cells

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…In recent years, there has been increasing attention on the natural antitumor compounds due to their biological activities and little or no side effects (Zhang et al, 2018;Kokudo et al, 2019;Li et al, 2019). Rhizopus nigrum is a zygote filamentous fungus that has been widely used in the brewing and pharmaceutical industries due to its biocatalytic and bio-transformative functions (Pan et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Role and Mechanism of Rhizopus Nigrum Polysaccharide EPS1-1 as Pharmaceutical for Therapy of Hepatocellular Carcinoma

Chu

Miao

Huang

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Objective: This work is to study the effect of Rhizopus nigrum polysaccharide EPS1-1 on hepatocellular carcinoma (HCC) in vitro and in vivo. Methods: HepG2 and Huh-7 cells and nude mice models of liver cancers were used in this study. The cells and nude mice were treated with EPS1-1 at different concentrations. The CCK8 assays were used to measure the proliferation activities of cells, apoptosis was determined with flow cytometry, cell migration was measured by wound-healing assays, cell invasion was evaluated by Transwell assay, and the survival periods of different groups of tumor-bearing mice were compared. Real-time PCR and Western blot were used to measure the expression levels of mRNAs and proteins of the genes related to proliferation, apoptosis, migration, and invasion. Results: In vitro experiments revealed that when treated with EPS1-1, HepG2 and Huh-7 cell proliferation activities decreased, while there was an increase for the apoptosis rate, and the migration and invasion capabilities were significantly reduced. In vivo experiments showed that EPS1-1 could significantly reduce the tumor growth and lung metastasis of HCC, and prolong the survival periods of tumor-bearing nude mice. Furthermore, EPS1-1 has no apparent damage to the heart, liver, and kidney. Further studies showed that EPS1-1 could affect the expression of proliferation-related genes CCND1 and c-Myc, apoptosis-related genes BAX and Bcl-2, and migration and invasion related genes Vimentin and Slug, thereby affecting the biological process of HCC. Conclusion: EPS1-1 can inhibit the malignant process of HCC in vitro and in vivo, which indicates that EPS1-1 has the potential value of clinical application as chemotherapy or adjuvant in the treatment of liver cancer.

show abstract

“…Recent preclinical studies and clinical trials combined the use of DC stimulators with the growth factor FMS-like tyrosine kinase-3 ligand (FLT3L) to increase DC numbers in peripheral blood [59,60]. For optimal delivery, the adjuvants can be encapsulated in nanoparticles, liposomes, or immunostimulatory complexes specifically targeting DCs [61][62][63], whereas to guarantee a sufficient availability of immunogenic TAAs, in situ vaccination can be combined with ICD-inducing therapeutic modalities, such as doxorubicine or radiotherapy.…”

Section: In Situ Vaccinationmentioning

confidence: 99%

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

et al. 2020

View full text Add to dashboard Cite

The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.

show abstract

Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size

Cited by 42 publications

References 18 publications

Stannic Oxide Nanoparticle Regulates Proliferation, Invasion, Apoptosis, and Oxidative Stress of Oral Cancer Cells

Stannic Oxide Nanoparticle Regulates Proliferation, Invasion, Apoptosis, and Oxidative Stress of Oral Cancer Cells

Role and Mechanism of Rhizopus Nigrum Polysaccharide EPS1-1 as Pharmaceutical for Therapy of Hepatocellular Carcinoma

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

Contact Info

Product

Resources

About